TENAX THERAPEUTICS INC

Tenax Therapeutics' institutional ownership was transformed almost overnight: $298.6 million in tracked institutional value across 71 holders as of the quarter ended March 31, 2026, up from a base where several of today's largest holders didn't exist a quarter earlier. T. Rowe Price Associates opened a brand-new $47.2 million position (2,951,116 shares), instantly the largest in the stock. Janus Henderson Group increased its stake nearly tenfold, from 166,666 to 1,815,474 shares (+$27.0 million), and Stonepine Capital Management grew an 11,884-share position into 975,200 shares — an 82-fold increase worth $15.4 million. Perceptive Advisors, a healthcare-focused specialist, more than tripled its holding (439,142 to 1,447,782 shares, +$17.8 million), while UBS Group grew a nominal 676-share stake to 381,419 shares. All of this activity accompanied roughly a 32% rise in TENX's share price. Against that wall of buying, selling was minimal — only two holders, Sphera Funds Management and Diadema Partners, trimmed their positions, and both cuts were modest by comparison.